Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG) Given Consensus Rating of "Moderate Buy" by Analysts

Key Points

• Hemab Therapeutics has a “Moderate Buy” consensus rating from seven analysts, with five buys, one hold and one sell. The average 12-month price target is $51.40, versus the stock’s recent price of $44.41.
• Analyst views include Evercore’s $50 outperform target, Goldman Sachs’ $36 buy target and HC Wainwright’s raised $60 buy target, while Weiss Ratings issued a sell rating.
• Insider and institutional activity was positive: major shareholder RA Capital bought 61,523 shares, and Braidwell LP acquired a new 160,000-share position. Hemab nevertheless reported quarterly EPS of -$0.80, below the -$0.63 consensus estimate.

Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Get Free Report) has received an average rating of "Moderate Buy" from the seven brokerages that are covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation and five have issued a buy recommendation on the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $51.40.

Several brokerages have issued reports on COAG. Evercore began coverage on shares of Hemab Therapeutics in a research report on Tuesday, May 26th. They issued an "outperform" rating and a $50.00 price target for the company. Wall Street Zen upgraded shares of Hemab Therapeutics to a "hold" rating in a report on Saturday, May 9th. The Goldman Sachs Group assumed coverage on shares of Hemab Therapeutics in a research note on Tuesday, May 26th. They issued a "buy" rating and a $36.00 price objective on the stock. Weiss Ratings assumed coverage on Hemab Therapeutics in a research report on Thursday, August 13th. They set a "sell (d+)" rating for the company. Finally, HC Wainwright lifted their target price on Hemab Therapeutics from $52.00 to $60.00 and gave the stock a "buy" rating in a report on Tuesday, August 11th.

Insider Activity

In related news, major shareholder Ra Capital Management, L.P. acquired 61,523 shares of the business's stock in a transaction that occurred on Tuesday, June 16th. The shares were bought at an average cost of $24.98 per share, with a total value of $1,536,844.54. Following the completion of the purchase, the insider directly owned 6,444,637 shares in the company, valued at $160,987,032.26. The trade was a 0.96% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Hemab Therapeutics stock. Braidwell LP purchased a new position in Hemab Therapeutics Holdings, Inc. (NASDAQ:COAG - Free Report) during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund purchased 160,000 shares of the company's stock, valued at approximately $5,877,000. Braidwell LP owned 0.34% of Hemab Therapeutics as of its most recent filing with the Securities and Exchange Commission.

Hemab Therapeutics Stock Up 0.1%

Shares of COAG stock opened at $44.41 on Friday. The firm has a market capitalization of $2.07 billion and a price-to-earnings ratio of -1.79. The company's 50-day moving average price is $45.23. Hemab Therapeutics has a 12 month low of $23.00 and a 12 month high of $55.42.

Hemab Therapeutics (NASDAQ:COAG - Get Free Report) last released its quarterly earnings data on Tuesday, August 11th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.63) by ($0.17). As a group, analysts forecast that Hemab Therapeutics will post -3.09 EPS for the current year.

About Hemab Therapeutics

Hemab Therapeutics is a clinical-stage biotechnology company focused on developing novel therapies for people with serious bleeding and thrombotic disorders. The company's research is centered on treatments designed to address diseases of the blood and coagulation system, with the goal of improving outcomes for patients who may not be adequately served by existing options.

Hemab's pipeline includes drug candidates aimed at rare hematologic conditions, including factor XI-related approaches and other programs in inherited bleeding disorders.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source